In a report released yesterday, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.

The company had focused its resources on Filspari’s launch in IgAN after the US FDA snubbed the therapy in another rare ...

Analyst Etzer Darout of BMO Capital maintained a Hold rating on Novartis (NVS – Research Report), retaining the price target of $118.00.

Skyrizi approved for ulcerative colitis; New pneumococcal vaccine; Indictment may impact as much as 50,000 ADHD patients; Results announced for Moderna’s next-gen COVID-19 vaccine; Farxiga ...

A Travere Therapeutics drug for a rare disease that can progress to kidney failure has converted its status to full FDA approval, strengthening the product’s case to compete against two other ...

Then the FDA in August handed Novartis’ complement inhibitor Fabhalta an accelerated approval. The Swiss pharma’s selective ETA receptor inhibitor, atrasentan, is also under FDA review.

Fabhalta (iptacopan) was approved by UK drugs regulator the MHRA last month, becoming an option for an estimated 220 out of ...

There is a simple discount patient access scheme for iptacopan. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Iptacopan (Fabhalta) is available on the NHS. It is a possible treatment for paroxysmal nocturnal haemoglobinuria in adults with haemolytic anaemia. Your healthcare professionals should give you clear ...

The National Institute for Health and Care Excellence (NICE) has published final guidance (TA1000) recommending Fabhalta® (iptacopan) as a treatment option in eligible patients on the NHS in England ...